Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency

NCT07385846 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma
Mismatch Repair Deficiency

Interventions

DRUG: Pembrolizumab
DEVICE: Navifus Focused Ultrasound Sonification

Sponsor

Jennifer Leddon

Collaborators

[object Object]